Welcome to our dedicated page for Trinity Biotech news (Ticker: TRIB), a resource for investors and traders seeking the latest updates and insights on Trinity Biotech stock.
Trinity Biotech plc reports developments across its commercial-stage diagnostics and health technology business, including clinical laboratory products, point-of-care testing, diabetes management solutions, and wearable biosensor development. Its updates frequently cover the Premier Hb9210 HbA1c laboratory blood glucose monitoring platform, TrinScreen HIV testing, and the CGM+ continuous glucose monitoring program.
Company news also addresses specialty diagnostics initiatives such as EpiCapture prostate cancer testing and autoimmune biomarker work supported by its New York State Department of Health-certified reference laboratory. Other recurring topics include commercial operations in North America, manufacturing and cost-control actions under its Comprehensive Transformation Plan, ADS-based financing arrangements, trading updates, and Nasdaq listing-status notices.
Trinity Biotech (Nasdaq: TRIB) has successfully regained compliance with two crucial Nasdaq listing requirements. The company has met the $1.00 per share minimum bid price requirement by maintaining a closing bid price at or above $1.00 for ten consecutive business days from August 12-25, 2025. Additionally, Trinity Biotech has satisfied the minimum market value of publicly held shares (MVPHS) requirement by maintaining an MVPHS of $15 million or greater for more than 10 consecutive business days.
This development resolves the compliance issues that arose on March 14, 2025, when the company received notices from Nasdaq regarding its failure to meet both requirements. While Trinity Biotech has regained compliance, the company acknowledges there is no assurance of maintaining these requirements in the future.
Trinity Biotech (Nasdaq: TRIB), a commercial-stage biotechnology company specializing in human diagnostics and diabetes management solutions, has appointed Paul Tivnan as a Non-Executive Director to its Board of Directors. Tivnan brings over 25 years of senior leadership experience in finance, capital markets, and corporate governance.
Currently serving as CFO of Deriva Energy LLC, Tivnan's notable experience includes leading Ardmore Shipping Corporation's NYSE IPO in 2013 as CFO. He holds multiple professional qualifications including being a Fellow of the Institute of Chartered Accountants of Ireland and a Certified International Director from INSEAD Business School.
The appointment aligns with Trinity Biotech's transformation strategy and focus on growth in diagnostics and wearable health technologies.
Trinity Biotech (Nasdaq: TRIB) has received regulatory approval to begin offshore and outsourced manufacturing of its flagship TrinScreen™ HIV rapid test. This strategic manufacturing transition follows a previous World Health Organization (WHO) approval and represents a crucial milestone in the company's transformation strategy.
The new manufacturing model is designed to deliver three key benefits: expanded gross margins, freed up working capital, and reduced fixed costs. The company has already initiated manufacturing under this new operational framework, which aims to maintain product integrity and regulatory compliance while improving cost-effectiveness and scalability.
Trinity Biotech (Nasdaq: TRIB) has received New York State Department of Health (NYSDOH) approval to launch its FDA-cleared PreClara™ Ratio biomarker test for preeclampsia risk assessment in Q3 2025. The test measures sFlt-1/PlGF ratio to evaluate progression risk to severe preeclampsia in hospitalized patients with hypertensive pregnancy disorders.
The test addresses a significant medical need, as approximately 500,000 U.S. women are affected annually by hypertensive pregnancy disorders. Recent studies show potential cost savings exceeding $10 million per 1,000 patients through reduced preterm deliveries and NICU admissions. This approval also supports the future launch of PrePsia™, Trinity's early pregnancy risk assessment technology.
Trinity Biotech (Nasdaq: TRIB) has announced breakthrough clinical trial results for its next-generation continuous glucose monitoring technology, CGM+. The trial demonstrated that their redesigned needle-free glucose sensor can deliver accurate readings over a 15-day wear period without requiring finger-stick calibration.
The company's innovative CGM+ platform features a modular design that reduces disposable components and integrates multiple health metrics including heart activity, body temperature, and physical activity data. This approach aims to significantly lower costs compared to existing market solutions, addressing accessibility barriers in the projected $28 billion CGM market by 2030.
Trinity Biotech (NASDAQ:TRIB) has announced the launch of its FDA-cleared PreClara™ Ratio (sFlt-1/PlGF) biomarker test for preeclampsia detection through its New York-based reference laboratory in Q3 2025. The test, developed in collaboration with Thermo Fisher Scientific, aims to address hypertensive disorders affecting approximately 500,000 women annually in the United States.
The test enables healthcare providers to make earlier, informed decisions for hospitalized patients by assessing the likelihood of progression to severe preeclampsia. Recent U.S. studies indicate potential neonatal cost savings exceeding $10 million per 1,000 patients when integrated into standard care, primarily through reduced preterm deliveries and NICU admissions.
This launch precedes the planned introduction of PrePsia™, Trinity Biotech's proprietary preeclampsia risk assessment technology for early pregnancy.
Trinity Biotech (Nasdaq: TRIB) has unveiled CGM+, an AI-native continuous glucose monitoring platform targeting the $260 billion AI wearable market. The next-generation wearable biosensor combines glucose monitoring with heart activity, temperature, and physical activity tracking in a single modular device.
The CGM+ platform features a minimally invasive electrochemical glucose sensor and proprietary needle-free technology, designed to reduce disposable components and lower care costs. The company anticipates a commercial launch in mid-2026, targeting both clinical and consumer health markets.
The global CGM market is projected to grow from $13.28B in 2025 to $28.72B by 2030 (16.68% CAGR). Trinity Biotech plans multiple revenue streams, including device sales, AI analytics subscriptions, and strategic partnerships with healthcare providers, insurers, and digital health platforms.
Trinity Biotech (NASDAQ: TRIB), a commercial stage biotechnology company, announced reaching a significant profitability milestone in Q2 2025, projecting to be Adjusted EBITDA-positive going forward. The company expects to achieve meaningful positive Adjusted EBITDA and cash flow from operations starting Q3 2025.
For Q1 2025, Trinity reported revenue of $7.6 million with a gross profit of $1.9 million and an operating loss of $6.5 million. The company projects Q2 2025 revenue to increase significantly to $11-12 million, driven by ramped-up manufacturing under its revised operational structure and normalized demand for rapid HIV tests.
Trinity Biotech continues development of its next-generation continuous glucose monitoring (CGM) solution, targeting the $13 billion global CGM market. The company recently completed a pre-pivotal trial on upgraded sensor technology and plans to unveil key aspects of its innovative design solution soon. Additionally, Trinity is advancing the international rollout of its upgraded diabetes care HbA1c testing product and TrinScreen HIV tests, while progressing on pipeline developments including preeclampsia screening and prostate cancer tests.
Trinity Biotech (NASDAQ:TRIB) has secured World Health Organization (WHO) approval for offshoring and outsourcing the upstream manufacturing of its flagship TrinScreen™ HIV rapid test. This strategic move, set to be implemented in Q3 2025, is a crucial part of the company's transformation plan aimed at improving financial performance and achieving sustainable profitability.
The transition from in-house operations to an outsourced model is expected to deliver significant improvements in gross margins, reduce fixed costs, enhance supply chain resilience, and free up working capital. The company will maintain product integrity and regulatory compliance while focusing internal resources on innovation and market expansion.